Prostate MRI–TRUS fusion biopsy: a review of the state of the art procedure.
Prostate cancer is the fourth most common cancer and population-based screening programmes are being increasingly adopted worldwide. Screening-positive patients undergo routine transrectal ultrasound (TRUS)-guided systematic biopsy, which is the current diagnostic standard for prostate cancer. Howev...
| Published in: | Abdominal Radiology Vol. 45; no. 7; pp. 2176 - 2184 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Published: |
Springer Nature
Jul2020
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143660685&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 143660685 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 2366004X JT14 jtl: Abdominal Radiology issn: 2366004X maglogo: N pubinfo: dt: Jul2020 vid: 45 iid: 7 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 143660685 10.1007/s00261-019-02391-8 143660685 ppf: 2176 ppct: 8 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Prostate MRI–TRUS fusion biopsy: a review of the state of the art procedure. aug: au: Das, Chandan J. Razik, Abdul Netaji, Arjunlokesh Verma, Sadhna affil: Department of Radiology, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, 110029, New Delhi, India sug: ab: Prostate cancer is the fourth most common cancer and population-based screening programmes are being increasingly adopted worldwide. Screening-positive patients undergo routine transrectal ultrasound (TRUS)-guided systematic biopsy, which is the current diagnostic standard for prostate cancer. However, systematic biopsies suffer from poor sensitivity, especially for the tumors of the anterior prostate and apex as well as in large volume glands. In the past decade, MRI-guided targeted biopsies have come up, which utilize the multiparametric capability of MRI to target lesions for sampling. MRI/TRUS fusion biopsies combine the advantages of MRI-targeting with that of real-time guidance made possible by TRUS. MRI–TRUS fusion biopsies are being increasingly used in men with high clinical suspicion of prostate cancer who have had prior negative systematic biopsies. A large number of fusion biopsy platforms are currently available commercially. Although the basic workflow is similar, there are differences in the operational software, biopsy routes offered, TRUS acquisition technique, type of correction applied at the time of fusion and in the probe tracking hardware. The article describes the current role and indications of MRI–TRUS fusion biopsy followed by a discussion on the workflow, patient preparation, biopsy procedure and complications. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|